Saturday 17 October 2026
Export IMRN’s income statement to Excel — free account
IMMURON
IMRN Healthcare Biotechnology
IMMURON’s revenue for fiscal 2026 (year ended June 2026) was $5.2 million, up 10.9% from fiscal 2025. Revenue growth for five consecutive years.
0.98
0.05
−4.85%
Follow IMRN
IMMURON (IMRN) P/E ratio
IMMURON has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2026 | 0.0× | — |
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2023 | 0.0× | — |
| Dec 2022 | 0.0× | — |
| Jun 2022 | 0.0× | — |
| Dec 2021 | 0.0× | — |
| 6 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| QNRX Quoin Pharmaceuticals, Ltd. Sponsored ADR compare | n/m |
| BOLT Bolt Biotherapeutics, Inc. compare | n/m |
| KPTI Karyopharm Therapeutics Inc. compare | n/m |
| IMRN IMMURON | n/m |
| SNTI Senti Biosciences, Inc. compare | n/m |
| ADIL Adial Pharmaceuticals, Inc. compare | n/m |
| XTLB XTL Biopharmaceuticals Ltd. compare | n/m |
| NKGN NKGen Biotech, Inc. compare | n/m |
| CSCIF COSCIENS Biopharma Inc. compare | 1.0× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)